Calliditas Therapeutics AB, a biopharma company, announced that the company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer”. This Notice of Allowance is expected to result in the issuance of a US patent once administrative processes are completed.
Genkyotex (Paris:GKTX) (Brussels:GKTX) (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib in healthy subjects.